[
  {
    "uuid": "d730a483a2be2de3aac78b41a9770968701b3865",
    "url": "https://www.meneame.net/story/sanchez-celebra-salida-vox-gobiernos-autonomicos-gran-dia-espana/c012",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "mariKarmo",
    "published": "2024-07-12T05:06:00Z",
    "title": "#12 Sánchez celebra la salida de Vox de gobiernos autonómicos: \"Es un gran día para España\"",
    "text": "Portada\nmis comunidades\notras secciones\nAl final el gobierno frankenstein, el que iba a reventar por un lado u otro, ahí sigue. Y mientras el PP teniendo que lidiar con una panda de paletos vociferantes como aliados, y ahora además con una escisión aún más paleta y aún más vociferante.\nPues voy a hacer de abogado del diablo. Lo primero de todo es que avisaron de salirse de los gobiernos si se cumplía lo del reparto de menores...y han cumplido. Seguramente si hubieran reculado ya estaríamos con el mantra de los sillones y las poltronas.\nSe está celebrando el reparto, cuando seguimos sin atajar el problema. Muchos de ellos no son menores, no tenemos información alguna suya previa y por mucho que digamos donde deberían estar es con sus familias.\nSupongo que desde la perspectiva de la \"izquierda\" esto es una fiesta. Pero no todo el mundo piensa igual y esto es un problema que ni los políticos de izquierda o derecha se van a comer en sus barrios y casas.\nLuego vendrán los sesudos análisis del auge de la ultra derecha.\nY bueno, ahora ya podéis tildarme de fascista o lo que os salga de las pelotas por no seguir el ideario estándar de la izquierda.\nTeniendo en cuenta el contexto, que vox es un partido de gente que ha demostrado tener poca capacidad de gestionar, que es un partido para hacer ruido en la oposición más que para gobernar (igual que podemos en este punto), y que esta crisis de los menores no es ni de lejos representativo del problema inmigratorio.\nPero hay que reconocer que esto es un gesto de honestidad que no recordamos en la política española. Renunciar a poltronas porque se han incumplido puntos que eran importantes para ellos desde el punto de vista de programa. Sobre cualquier otro partido (desde el PP a indepes o el psoe) hay cientos de ejemplos de lo contrario, de aferrarse al sillón y capear las preguntas con una desvergüenza acojonante.\nTodo por repartirse 300-400 niños entre 44 millones de españoles, niños que ya están en España (sí, Canarias, señor Abascal, es España y hay que ser solidaria con ella, que también hay españoles allí) y cosa que lleva haciéndose cada año. Ultra\"católicos\" negando el auxilio a niños. VAYA VAYA.\nEs que no dan para más. Ni honor ni pollas, es que son tontos. El \"honor\" es para las batallas, no para la política.\nMe arremango el fajín y apurandome el Cinzano promulgo:\n-Hay un movimiento divertido en la derecha, al crecer Vox, el PP se vio obligado a endurecer sus posturas mas escoradas para intentar recuperar los votos del ala mas reaccionaria que se iban desangrando pa Vox, eso es lo que vimos estos años, un \"a ver quien dice la idiotez mas gorda\". Esta semana asistimos a una nueva dinámica encabezada por el follaardillas, Vox ha visto como le crece un enano por la derecha, no puede permitirlo, o sea q se enfurruñan y se cierran en banda haciendo bandera de... pos algo tan propagandistico y de impacto entre el electorado mas ultra como los MENAS... (Aunque sea algo tan anecdótico como 21 personas, muchos niños, pa acoger en una comunidad como Castilla.... q lo pones en perspectiva y dices q cojones 21 personas no tienes donde meterlas en la españa vacia???? Esto no es \"problema\" esto es publicidad pa sus cafeteros) Con lo que puede ojo puede, que el PP vuelva a intentar pegar un giro hacia el centro (con el debilitamiento del ala dura del partido, Ayuso juapa, te miro a ti q ultimamente estas muy callada) y dejar que Vox y Alvise se maten a garrotazos a ver quien es mas y muy Ejpañó\nGolpe en la barra erupto, niño ponte una tapita aqui anda, que hay que darle culto al cuerpo",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "spanish",
    "sentiment": "positive",
    "categories": [
      "Human Interest",
      "Politics",
      "War, Conflict and Unrest"
    ],
    "ai_allow": false,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [],
      "locations": []
    },
    "rating": null,
    "crawled": "2024-07-12T10:17:41.382+03:00",
    "updated": "2024-07-12T10:17:41.382+03:00"
  },
  {
    "uuid": "b4baab117c15db3b3a6b24c074f2946406eb3ccf",
    "url": "https://www.lapatilla.com/2024/08/22/cupula-militar-chavista-se-suscribio-a-la-polemica-sentencia-de-la-sala-electoral-del-tsj",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Capablanca",
    "published": "2024-08-22T21:16:00Z",
    "title": "Cúpula militar chavista se suscribió a la polémica sentencia de la Sala Electoral del TSJ",
    "text": "Vladimir Padrino López.\nLa Fuerza Armada Nacional Bolivariana (Fanb) se suscribió este jueves a la polémica sentencia de la Sala Electoral del Tribunal Supremo (TSJ) que ratificó los resultados de la pasada elección presidencial, pese a que no se sometieron a la verificación internacional independiente ni cumplieron con los requisitos de las leyes vigentes.\nlapatilla.com\n“La Fuerza Armada Nacional Bolivariana acata de manera absoluta y categórica la sentencia emitida por la Sala Electoral del Tribunal Supremo de Justicia que declara con lugar el recurso contencioso relativo a los comicios presidenciales del pasado 28 de julio de los corrientes, convalidando los resultados emitidos previamente por el CNE”, comenta el texto publicado por el mayor general Vladimir Padrino López en sus redes sociales.\n“Ratificamos absoluta lealtad al ciudadano Nicolás Maduro Moros, presidente constitucional de la República Bolivariana de Venezuela, reelecto por el Poder Popular, legítimamente proclamado por el Poder Electoral y ahora ratificado por el máximo tribunal de justicia del país”, agregó el comunicado.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "spanish",
    "sentiment": "negative",
    "categories": [
      "War, Conflict and Unrest",
      "Social Issue",
      "Politics"
    ],
    "ai_allow": true,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [],
      "organizations": [],
      "locations": []
    },
    "syndication": null,
    "rating": null,
    "crawled": "2024-08-23T00:26:33.449+03:00",
    "updated": "2024-08-23T00:26:33.449+03:00"
  },
  {
    "uuid": "8622c81035ebc21c5eca6e2fd6357386659d368d",
    "url": "https://watcher.guru/news/polygon-matic-weekend-price-prediction",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Sahana Kiran",
    "published": "2023-12-28T23:30:00Z",
    "title": "Polygon MATIC Weekend Price Prediction",
    "text": "Polygon’s native token, MATIC, has recently experienced a surge in positive market momentum, evident in both its daily and weekly charts turning green. According to data from CoinMarketCap, MATIC’s value has surged by more than 18% within the last 24 hours, signaling strong performance in the market. This article delves into Polygon MATIC’s current market status, and achievements, and explores predictions for its weekend price. Current Market Overview As of the latest update, MATIC is actively traded at $1.02, boasting a market capitalization exceeding $10 billion. The significant surge in value observed over the past 24 hours reflects the optimistic sentiment surrounding Polygon’s native token. [Also Read: Polygon (MATIC) Spikes 23%, Reaches $1.07: Can it hit $2 Next?](https://watcher.guru/news/polygon-matic-spikes-23-reaches-1-07-can-it-hit-2-next) Achievements of Polygon’s zkEVM Sandeep Nailwal, the co-founder of Polygon, recently drew attention to a notable achievement of the zk rollup technology. In a post on X (formerly Twitter), Nailwal highlighted that among the top 15 roll-ups by Total Value Locked (TVL) and adoption, four are being constructed using the Polygon zk-tech stack. This accomplishment underscores the widespread adoption and capabilities of Polygon’s zk Stack. MATIC’s Trajectory in 2023 Analyzing the technical aspects of Polygon’s MATIC for the year 2023, projections indicate a minimum expected cost of $0.8087. The anticipated maximum level for MATIC’s price is set at $0.9193, with an average trading price expected to hover around $0.8938. Weekend Price Forecasts Aligned with broader market trends, MATIC is expected to experience an upward trend over the upcoming days. According to data sourced from CoinCodex, MATIC is forecasted to rise to $1.12 on Dec. 30. As the weekend unfolds, the altcoin is predicted to surge further, reaching $1.20 by Sunday, Dec. 31. Furthermore, these predictions reflect positive momentum and potential gains for the asset as the year concludes. [Also Read: Polygon New Year Price Prediction: How High Can MATIC Go?](https://watcher.guru/news/polygon-new-year-price-prediction-how-high-can-matic-go) Polygon’s MATIC has attracted attention due to its recent bullish momentum. The accomplishments of Polygon’s zk rollup technology, as highlighted by co-founder Sandeep Nailwal, underscore the platform’s growing influence. As the asset progresses through 2023, the weekend predictions suggest a positive trajectory, reaching $1.20 on the last day of the year.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Science and Technology",
      "Economy, Business and Finance"
    ],
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "matic",
          "sentiment": "none"
        },
        {
          "name": "sandeep nailwal",
          "sentiment": "none"
        },
        {
          "name": "nailwal",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "matic",
          "sentiment": "none"
        }
      ],
      "locations": [
        {
          "name": "matic",
          "sentiment": "none"
        }
      ]
    },
    "rating": null,
    "crawled": "2023-12-29T02:19:35.871+02:00",
    "updated": "2023-12-29T06:10:31.293+02:00"
  },
  {
    "uuid": "2fa4297953e5713f5ecabb5c4aa26619b592011d",
    "url": "https://www.gmanetwork.com/news/scitech/weather/906385/why-are-some-areas-colder-despite-extreme-heat-pagasa-explains/story",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "SUNDY LOCUS and VINCE ANGELO FERRERAS,GMA Integrated News",
    "published": "2024-05-10T08:17:00Z",
    "title": "Why are some areas 'colder' despite extreme heat? PAGASA explains | GMA News Online",
    "text": "Dry weather, exacerbated by the El Niño phenomenon, has left many Filipinos drenched in sweat.\nBut for Silvestre Aben, who grew up in Benguet, it remains cool up north despite the extreme heat in most parts of the country.\n\"For this time, mga 26 degrees Celsius. Kung sa hapon, bababa pa ng mga 24°C to 25°C. Talagang ganito ang temperature dito sa Benguet,\" he told GMA News Online.\n(For this time, it’s 26 degrees Celsius. In the afternoon, it reaches between 24°C and 25°C. This is how the temperature is here in Benguet.)\n\"Walang pinagbago. Talagang ganun ang weather dito sa Benguet. Kapag aakyat ka pa sa north, mas malamig doon,\" Aben added.\n(Nothing really changed. That’s how the weather is in Benguet. If you go up north, it’s colder there.)\nState weather bureau PAGASA has recorded dangerous levels of heat indexes across the country since March.\nHeat index is the measure of the temperature that a person feels in contrast to the actual air temperature. It is computed by factoring in the humidity and the air temperature, according to the state weather bureau.\nOn April 28, the heat index in Iba, Zambales, rose to an extremely dangerous level of 53°C — the highest in the country so far this year.\nAround 25 areas also reported dangerous levels of heat indexes of up to 45°C on May 9.\nTopography\nBut despite the extreme heat, some areas remained relatively cooler, reporting lower heat indexes. These include Baguio City, La Trinidad, Benguet, and Tanay, Rizal.\nIn the last five days, La Trinidad reported heat indexes of 25°C (May 9), 27°C (May 8), 29°C (May 7), 26°C (May 6), and 27°C (May 5).\nMeanwhile, Baguio monitored heat indexes of 25°C (May 9), 27°C (May 8), and 28°C (May 5 to May 7).\nThe municipality of Tanay experienced heat indexes of 34°C (May 9), 32°C (May 8), 33°C (May 7), 32°C (May 6), and 33°C (May 5).\nJohn Manalo, a PAGASA weather specialist, explained that an area's terrain has an impact on the heat index.\n“Maraming factors na nagpapataas o nagpapababa ng heat index measurements na nao-obserbahan natin. Isa po dito ay 'yung elevation or 'yung topography,” said Manalo.\n(There are many factors affecting heat index measurements. One of the factors is elevation, or the area’s topography.)\n“'Yung mga lugar na nasa highly-elevated o 'yung matataas gaya ng Baguio…relatively, mas malamig o lower 'yung temperature..as compared sa mga low-lying areas, halimbawa, Metro Manila,” he added.\n(Highly elevated areas such as Baguio City experience lower temperatures compared to low-lying areas like Metro Manila.)\n“May role din ang distance from the nearest body of water…Kung sa Manila Bay, the more na mas malapit sa body of water, mas may tendency na mas mataas ang relative humidity dahil sa moisture content na dala ng mga body of water,” Manalo said.\n(An area’s distance to the nearest body of water also plays a role. Coastal areas such as Manila Bay have higher relative humidity due to the moisture content of the body of water.)\nWarmer Baguio\nAlthough Baguio is known for its cold climate, Sam Silverio noticed that today’s heat is different from the previous years.\n“Hindi ganun kainit compared sa Manila, pero mainit pala compared to usual Baguio weather,” she told GMA News Online.\n(It’s not that hot compared to Manila, but this is hotter compared to the usual Baguio weather.)\n“Gumigising na ako madalas basa ng pawis eh (I now often wake up sweating).''\nRachel Santos said that the heat in Tanay is still bearable compared to Metro Manila, but she also noticed that it is different from the past.\n“As compared sa mga nagdaang summer season, iba talaga yung init ngayon kahit saan,” she told GMA News Online.\n(As compared to the previous summer seasons, it is very hot anywhere else.)\nPAGASA said the infrastructure and establishments in an area can also influence the heat index. Dubbed the “urban heat island effect,'' cities record warmer indexes than rural areas due to the buildings and establishments around them.\n“Ang urban areas ay relatively mas warmer compared sa nearby rural areas niya dahil sa differences sa structures and materials na nakikita natin sa urban areas,” said Manalo.\n(Urban areas are relatively warmer than rural areas because of the differences in structures and materials.)\n“Ang main difference nila ay heat capacity…Mas maraming buildings, mas may tendency na ma-hold nila yung warm air. Unlike sa rural na magdi-dissipate agad ang warm air, sa rural naga-accumulate siya and imbis na mapunta sa upper part ng atmosphere, nagt-transfer pa siya from one building to another o hino-hold pa siya ng asphalt o concrete or metals na meron kadalasan sa urban areas,” he added.\n(The main difference is the heat capacity. Buildings tend to hold warm air, unlike in rural areas where the warm air easily dissipates. The warm air in urban areas accumulates and even transfers from one building to another. The asphalt, concrete, and metal materials in urban areas also hold warm air.)\nIn Benguet, Aben said that it’s much cooler back in the day when there were still more trees.\n“Nung bata pa kami, malamig na malamig nun. Kasi marami pang kahoy nun, pero ngayon wala na, naubos na ang kahoy,” he said.\n(When we were young, it was very cold then. Because there were still many trees, but there are fewer of them now.) — VBL, GMA Integrated News",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "negative",
    "categories": [
      "Weather"
    ],
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "kung",
          "sentiment": "none"
        },
        {
          "name": "silvestre aben",
          "sentiment": "none"
        },
        {
          "name": "aben",
          "sentiment": "none"
        }
      ],
      "organizations": [
        {
          "name": "el niño",
          "sentiment": "negative"
        },
        {
          "name": "pagasa",
          "sentiment": "negative"
        }
      ],
      "locations": [
        {
          "name": "benguet",
          "sentiment": "none"
        }
      ]
    },
    "rating": null,
    "crawled": "2024-05-10T12:16:53.219+03:00",
    "updated": "2024-05-10T12:16:53.219+03:00"
  },
  {
    "uuid": "640ca5dee3fac7ea6e99de5ff26c412208fbf05a",
    "url": "https://www.schooltube.com/the-pontine-marshes-from-malaria-infested-swamp-to-agricultural-hub",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "SchoolTube Community",
    "published": "2024-07-04T21:45:00Z",
    "title": "The Pontine Marshes: From Malaria-Infested Swamp to Agricultural Hub | SchoolTube",
    "text": "The Pontine Marshes: From Malaria-Infested Swamp to Agricultural Hub The Pontine Marshes, a vast expanse of swampy land south of Rome, were once a symbol of Italy’s neglected south. Malaria-ridden and largely uninhabitable, the marshes presented a significant obstacle to development. However, under the fascist regime of Benito Mussolini, the Pontine Marshes underwent a dramatic transformation, becoming a testament to the ambition and ruthlessness of the Italian dictator. A History of Neglect For centuries, the Pontine Marshes had been a source of misery and disease. The stagnant water provided a breeding ground for mosquitoes, spreading malaria that decimated local populations. The marshlands also hindered agricultural development, making the region economically stagnant. Despite various attempts by previous governments to drain the marshes, their efforts proved largely unsuccessful. Mussolini’s Vision In the 1930s, Mussolini, seeking to showcase the power and efficiency of his regime, turned his attention to the Pontine Marshes. He envisioned transforming the swamp into a fertile agricultural hub, a symbol of Italy’s national rejuvenation. This ambitious project, known as the “Bonifica integrale” (integral reclamation), was intended to create new settlements, generate jobs, and boost agricultural production. Engineering Marvels The reclamation project involved massive engineering feats. Thousands of workers, many of them unemployed or refugees from the Depression, were mobilized to drain the marshes. A network of canals and drainage channels was constructed, along with pumping stations to remove excess water. The reclaimed land was then divided into plots, ready for cultivation. The project also involved the construction of new towns, such as Littoria (later renamed Latina), designed to accommodate the newly settled population. These towns featured modern infrastructure, including schools, hospitals, and public spaces, showcasing the modernizing ambitions of the fascist regime. Sacrifices and Controversy The reclamation of the Pontine Marshes came at a significant cost. The harsh working conditions, including exposure to malaria and other diseases, resulted in numerous deaths. The project also involved forced labor and the displacement of local communities, raising ethical concerns about the regime’s disregard for human rights. Despite the controversy, the Pontine Marshes reclamation project was a technical success. The marshes were drained, malaria was eradicated, and the region became a significant agricultural producer. The project also contributed to the expansion of Italy’s population and the creation of new economic opportunities. Legacy of the Pontine Marshes Today, the Pontine Marshes stand as a testament to Mussolini’s ambitious vision and the power of engineering. The region is known for its fertile land, which produces a variety of crops, including tomatoes, grapes, and olives. The reclaimed land has also become a popular tourist destination, offering opportunities for hiking, birdwatching, and exploring the history of the region. However, the legacy of the Pontine Marshes is also marked by the human cost of the project. The forced labor, the displacement of communities, and the disregard for human rights are reminders of the dark side of Mussolini’s regime. The reclamation project serves as a powerful reminder of the complexities of history and the need to consider both the positive and negative aspects of any historical event. Conclusion The transformation of the Pontine Marshes from a malaria-infested swamp to a thriving agricultural hub is a remarkable story. It showcases the ambition and engineering prowess of the fascist regime, while also highlighting the human cost and the ethical complexities of the project. The Pontine Marshes remain a fascinating example of how human intervention can reshape the landscape, but also a reminder of the importance of considering the impact of our actions on both the environment and human society.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Human Interest",
      "Environment"
    ],
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "mussolini",
          "sentiment": "none"
        },
        {
          "name": "benito mussolini",
          "sentiment": "none"
        }
      ],
      "organizations": [],
      "locations": [
        {
          "name": "rome",
          "sentiment": "none"
        },
        {
          "name": "italy",
          "sentiment": "none"
        }
      ]
    },
    "rating": null,
    "crawled": "2024-07-05T02:35:49.433+03:00",
    "updated": "2024-07-05T02:35:49.433+03:00"
  },
  {
    "uuid": "f6b9363772069a9224c97584f88c91567e28ca6f",
    "url": "https://webreprints.djreprints.com/2479693.html",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "Takushi Eliah",
    "published": "2024-04-11T20:59:00Z",
    "title": "New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding",
    "text": "New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding\nSeveral blood thinners are being developed that could prevent the clots that cause heart attacks and strokes—without some of the side effects\nUntil now, preventing clots has often come at the price of a higher risk of bleeding, ILLUSTRATION: EVA VAZQUEZ\nA new class of anticoagulant drugs on the horizon is taking fresh aim at one of cardiology’s toughest challenges: how to prevent blood clots that cause heart attacks and strokes, without leaving patients at risk of bleeding.\nAt least a half-dozen experimental blood thinners are in development that inhibit a protein called factor XI, one of several blood factors that regulate how the body forms clots.\nThe challenge is this: The body generates two types of clots—good ones that plug holes in blood vessels to stop bleeding caused by external injuries, and bad ones that grow inside arteries and veins. These can block blood flow to critical organs, potentially leading to injury or death.\nFor decades, drugs developed to prevent the bad clots have targeted proteins involved in forming both types of clots. As a result, preventing clots often comes at the price of a higher risk of bleeding, causing many patients to refuse to take, or stop taking, the medicine.\n“Too low of a dose, you clot; too high of a dose, you bleed,” says Dr. Michael Gibson, cardiologist and CEO at the nonprofit Baim Institute for Clinical Research at Harvard Medical School. “Our goal is to keep people from falling off the balance beam. This is what we have been chasing for years.”\nFactor XI, it turns out, is crucial for the formation of the bad clots inside blood vessels, what doctors call thrombosis. But researchers now believe that factor XI, unlike other blood factors, plays a minimal role in forming the good clots that stop bleeding. That suggests drugs against it could prevent the bad clots without significantly disrupting the process that causes good clots, and thus minimize excess bleeding associated with anticoagulants and other blood thinners.\nImportant questions about the effectiveness of factor XI inhibitors have yet to be answered, and success isn’t ensured. Several large-scale or Phase 3 clinical trials are now under way to determine the clinical and economic potential of the new agents. Results are expected later this decade.\nAt this stage, Factor XI inhibitors “appear to have good safety but maybe not as good efficacy as we would like,” says Richard Kovacs, professor at Indiana University Medical School, Indianapolis, and chief medical officer of the American College of Cardiology, who isn’t involved with the research.\n“There isn’t such thing as a free lunch. Maybe that applies here,” he says, adding that more research is needed to determine what role the drugs may play in clinical practice.\nA big advance\nAny factor XI agent that reaches the market would likely represent an important advance over drugs called factor Xa inhibitors, a blockbuster class of medicines dominated by Eliquis and Xarelto. Since they were approved just over a decade ago, these drugs have supplanted warfarin as the standard-of-care anticoagulant to prevent stroke in patients with the heart-rhythm disorder atrial fibrillation as well as other indications.\nLast year alone, Eliquis, marketed by Bristol-Myers Squibb and Pfizer , and Xarelto, from Johnson & Johnson and Bayer, racked up combined worldwide sales of about $19 billion. But while the drugs sharply reduce risk of life-threatening and other serious bleeding, including bleeding in the brain, associated with warfarin, patients taking them remain at risk for such side effects as nosebleeds, bleeding gums and gastrointestinal bleeding that can affect their quality of life or even land them in the hospital.\nAs a result, studies show, an estimated 40% to 60% of atrial-fibrillation patients refuse to take, stop taking or skip doses of the anticoagulants—or their doctors decide not to prescribe them. That leads to more than 50,000 preventable strokes each year in the U.S. alone.\nThe factor Xa inhibitors “really changed the landscape” for anticoagulation, “but bleeding is still the major complication,” says Jeffrey Weitz, a professor and coagulation expert at McMaster University in Hamilton, Ontario, who advises several companies developing factor XI drugs. “If we could have something that is at least as effective and safer, that could take us to the next step.”\nTesting the possibilities\nAn important driver of the effort is research showing that people born with low levels of factor XI suffer fewer strokes and other thrombotic events such as heart attacks than those with normal or elevated levels of the protein. They also are less prone to excessive bleeding, for example during surgery, than those with higher levels of factor XI. Moreover, they don’t appear to suffer any ill effects from being deficient in factor XI.\nBristol-Myers and J&J, rivals in the factor Xa market, have joined forces to make a huge bet on factor XI with a twice-a-day pill called milvexian. Their multibillion-dollar program includes Phase 3, or late-stage, trials for stroke prevention in atrial fibrillation and two other major indications—preventing recurrent events in patients who have already had an acute coronary episode such as a heart attack, or a stroke—with plans to enroll more than 46,000 patients. Milvexian targets the activated, or clot-initiating, form of factor XI, called factor XIa. Harvard’s Gibson is leading one of the trials.\nAlso in the mix is Anthos Therapeutics, a startup launched in 2019 by Blackstone Life Sciences, a unit of the private-equity firm Blackstone Group, to develop an antibody called abelacimab against factor XI. Anthos obtained rights to the drug from Novartis, which retains a royalty interest in it.\nMerck, Ionis Pharmaceuticals and closely held Aronora have agents earlier in development aimed at various clot-related ailments.\nAnthos provided a boost for agents against factor XI at the annual scientific meeting of the American Heart Association in November. There, researchers reported that abelacimab showed a striking 67% reduction in bleeding risk when tested against Xarelto in a study of 1,287 patients with atrial fibrillation at moderate to high risk of a stroke.\nSuch an advantage on bleeding against a factor Xa inhibitor “was really a game changer,” says Dr. Christian Ruff, director of general cardiology at Brigham and Women’s Hospital, Boston, who led the trial.\nMoreover, patients treated with abelacimab, delivered once a month by injection, had a 93% reduction in gastrointestinal bleeding compared with those taking Xarelto. GI bleeding accounts for about three-quarters of bleeding events that lead to hospitalization for atrial-fibrillation patients.\nBut while the reduction in bleeding indicates the drug is safer than a factor Xa inhibitor, the trial wasn’t large enough to show whether abelacimab was at least as effective in preventing stroke as Xarelto, leaving the efficacy question unanswered.\nA week later, Bayer, a third contender in the factor XI race, stunned cardiologists with the announcement that a Phase 3 study of its factor XIa inhibitor asundexian was stopped early for lack of efficacy in preventing stroke in atrial-fibrillation patients when tested against Eliquis.\nPressing ahead\nWeitz believes asundexian was ineffective because the dose in the study was too low. Bristol-Myers, J&J and Anthos say they remain confident in prospects for their respective agents. For its part, Bayer says it is reviewing data from its study and plans to publish its findings “in due time.” It is continuing a Phase 3 trial of the drug to prevent recurrent stroke and weighing its options for other indications, including in atrial-fibrillation patients.\n“We continue to believe in the promise of factor XIa inhibitors, and in asundexian,” the company says.\nIn any event, the failure of the asundexian study means just two factor XI agents have emerged as front-runners in a race to reach the market for stroke prevention in atrial-fibrillation patients—a total market in the U.S. of six million patients that the U.S. Centers for Disease Control and Prevention expects to grow to 12.1 million by 2030.\nAnthos, which had the big bleeding win in a study against Xarelto, is enrolling about 1,900 patients in a Phase 3 trial testing abelacimab against placebo among some atrial-fibrillation patients. The study is targeting only the estimated 40% to 60% of atrial-fibrillation patients who, because of bleeding risk or fear of bleeding, aren’t taking a factor Xa inhibitor or another anticoagulant such as warfarin or the antithrombin drug dabigatran. The strategy could narrow its market for the drug, at least initially, but the company believes it will have no trouble proving efficacy in preventing stroke against placebo. Results could come in 2025.\n“Those are the patients who really need an anticoagulant that’s safer,” says Dr. Dan Bloomfield, Anthos’s chief medical officer. Essentially “placebo is what they’re taking anyway.” Results could come as early as next year. Anthos is also testing abelacimab in certain cancer patients with a blood-vein clotting condition called venous thromboembolism.\nBristol-Myers and J&J are testing milvexian in a 15,500-patient head-to-head trial against Eliquis. The challenge is to show the drug is at least as effective in preventing stroke as Eliquis with a significantly lower bleeding risk. Results are expected in 2027.\nIf the trials are successful, the timing in both cases suggests the drugs could reach the market just as Eliquis and Xarelto lose patent protection and cheaper generic versions become available. Drugs will likely have to show a significant benefit against factor Xa inhibitors to gain traction against generic competition, researchers say.\nLow bleeding risk could also make factor XI inhibitors candidates to help prevent recurrent events in patients who have already suffered a stroke or an acute coronary event such as a heart attack—a potentially huge new market for anticoagulants. Standard of care for such patients are antiplatelet drugs such as clopidogrel, ticagrelor and aspirin, regimens that have sharply limited or ruled out adding anticoagulants that increase a patient’s bleeding risk. Bristol-Myers and J&J could see the results of their studies in these indications in 2026.\n“It’s an exciting hope that we can find drugs that will prevent [stroke] associated with atrial fibrillation without increasing the bleeding,” says Dr. Mariell Jessup, chief science and medical officer at the American Heart Association, who isn’t involved in the research. “If this is efficacious, it will change many, many things” about treatment of cardiovascular disease.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
      "Science and Technology",
      "Health"
    ],
    "external_links": [],
    "external_images": [],
    "entities": {
      "persons": [
        {
          "name": "eva vazquez",
          "sentiment": "none"
        }
      ],
      "organizations": [],
      "locations": []
    },
    "rating": null,
    "crawled": "2024-04-12T01:25:27.068+03:00",
    "updated": "2024-04-12T01:25:27.068+03:00"
  }
]